Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The 3' untranslated regions (3'-UTRs) of pro-apoptotic gene messenger RNAs (mRNAs) are critical regulatory segments located downstream of the coding sequence that govern the post-transcriptional fate of transcripts encoding cell death-inducing proteins. These regions contain binding sites for microRNAs (miRNAs) and RNA-binding proteins (RBPs) that modulate mRNA stability, transport, and translational efficiency (Source: Nature Reviews Genetics, 2014). In oncogenesis, the 3'-UTRs of pro-apoptotic genes such as BCL2L11 (BIM), BAX, and PMAIP1 (PUMA) are often targeted by overexpressed oncogenic miRNAs, leading to reduced protein expression and subsequent resistance to apoptosis (Source: Journal of Biological Chemistry, 2012). Conversely, in neurodegenerative disorders, aberrant interactions at these 3'-UTRs can lead to the pathological upregulation of pro-apoptotic factors, contributing to premature cell death (Source: Frontiers in Molecular Neuroscience, 2018). Therapeutic strategies aimed at these regions include antisense oligonucleotides (ASOs) and miRNA-based therapies designed to either block inhibitory miRNA binding or stabilize the mRNA to restore apoptotic sensitivity in malignant cells (Source: Nature Reviews Drug Discovery, 2017). Small molecule inhibitors that specifically target RNA secondary structures within these 3'-UTRs are also an emerging area of drug development to modulate protein levels (Source: Cell Chemical Biology, 2020). By influencing the rheostat of pro- and anti-apoptotic signals, these 3'-UTRs serve as pivotal checkpoints in determining cell survival or death.
Modulation of mRNA stability and translation efficiency through competitive binding or steric hindrance of microRNA and RNA-binding protein sites to increase pro-apoptotic protein expression.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 3' untranslated regions of pro-apoptotic gene messenger RNAs (Pro-apoptotic mRNA 3'-UTRs).